China-based Sichuan Kelun-Biotech Biopharmaceutical Co Ltd announced on Monday that the company has been granted investigational new drug (IND) clearance to initiate the clinical study of its potential first-in-class innovative antibody drug conjugate (ADC), SKB518, from the US Food and Drug Administration (FDA).
In June 2024, the company received a clinical trial notice approving the IND application for SKB518 for advanced solid tumours from Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The Phase 1 clinical trial for SKB518 is ongoing in China.
Developed by Kelun-Biotech, SKB518 is a novel ADC drug with potential first-in-class target and proprietary intellectual property rights based on the biological characteristics of the target and using the technology of the OptiDCTM platform. It has demonstrated promising efficacy and safety in preclinical studies and is intended to be used for the treatment of advanced solid tumours.
Nordic Bioscience launches new Endotrophin assay
Endo adds new concentration to ADRENALIN ready-to-use premixed bag line
OS Therapies launches OS Animal Health to target USD150m canine osteosarcoma market
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties
FDA extends Biohaven's PDUFA date for troriluzole NDA for spinocerebellar ataxia
GC Biopharma secures FDA approval for US plasma centre
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software
Benuvia Operations enters Dronabinol API commercial supply agreement with US pharmaceutical company